Association Study of rs10090154 and rs1691053 With Predisposition to Prostate Adenocarcinoma in the Iranian Population

Document Type : Research Articles

Authors

• Roya Dehquan Dehnavi ¹
• Seyed Abdolhamid Angaji ²
• Behnaz Beikzadeh ³
• Hengameh Alibeik ¹
• Raheleh Roudi ⁴
• Behzad Narouie ⁵

¹ Department of Biological Sciences, North Tehran Branch Islamic Azad University, Tehran, Iran

² Department of Cell and Molecular Biology, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran

³ Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran

⁴ Department of Radiology, Stanford University, Stanford, CA 94305, USA

⁵ Department of Urology, Zahedan University of Medical Sciences, Zahedan, Iran

https://doi.org/10.22067/jcmr.2023.79067.1055

Abstract

Prostate cancer is the second most prevalent malignancy in men and the fifth leading cause of death worldwide. It is the second most common urinary tract cancer among Iranian men. The aim of this study was to investigate the association between rs10090154, located on the 8q24 locus, and rs1691053 on chromosome 5p15.31, with prostate adenocarcinoma and PSA levels. This study also aimed to identify the potential of these genetic markers as screening factors. This case-control study included 79 patients with prostate adenocarcinoma aged between 48 to 86 years, as well as 98 patients with benign prostatic hyperplasia aged between 47 to 81 years. The Tetra-primer ARMS-PCR method was applied to determine the genotype of each participant. In this study, no significant differences in genotypic distribution between the prostate adenocarcinoma and control groups were discovered for rs10090154 (P-value = 0.608) and rs1691053 (P-value = 0.102) polymorphisms. Moreover, for the study of the additive genetics model of the rs10090154 polymorphism, with the TT genotype as the reference, the CC genotype with P-value = 1 and OR {95%CI} = 0.750, {0.039-14.576} and CT genotype with P-value = 0.324 and OR {95%CI} = 0.577, {0.191-1.739}, were not associated. Correspondingly, for rs1691053, with the CC genotype as the reference, the CT genotype with P-value = 0.176 and OR {95%CI}= 0.196, {0.022-1.793}, and the TT genotype with P-value= 0.464, OR{95%CI}= 0.125, {0.005-3.225}, were not associated. These findings suggest that rs10090154 and rs1691053 may not be associated with prostate cancer among Iranians. However, further research with larger sample sizes and investigation of various Iranian subpopulations are needed to confirm these results.

Keywords

• prostate adenocarcinoma
• Association
• Tetra-primer ARMS-PCR
• 8q24
• 5p15.31

20.1001.1.20089147.2023.14.2.6.2

References

Alvarez-Cubero M. J., Saiz M., Martinez-Gonzalez L. J., Alvarez J. C., Lorente J. A. and Cozar J. M. (2013) Genetic analysis of the principal genes related to prostate cancer: a review. Urologic Oncology 31:1419-1429.

Audet-Walsh É., Yee T., Tam I. S. and Giguère V. (2017) Inverse Regulation of DHT Synthesis Enzymes 5α-Reductase Types 1 and 2 by the Androgen Receptor in Prostate Cancer. Endocrinology 158:1015-1021.

Baade P. D., Yu X. Q., Smith D. P., Dunn J. and Chambers S. K. (2015) Geographic disparities in prostate cancer outcomes--review of international patterns. Asian Pacific Journal of Cancer Prevention 16:1259-1275.

Bracarda S., de Cobelli O., Greco C., Prayer-Galetti T., Valdagni R., Gatta G.,et al. (2005) Cancer of the prostate. Critical Reviews in Oncology/Hematology 56:379-396.

Bunting P. S. (1995) A guide to the interpretation of serum prostate specific antigen levels. Clinical Biochemistry 28:221-241.

Casado E., Borque-Fernando A., Caamaño M., Graña J., Muñoz-Rodríguez J. and Morote J. (2022) Multidisciplinary Consensus on the Prevention and Treatment of Osteoporosis and Fragility Fractures in Patients with Prostate Cancer Receiving Androgen-Deprivation Therapy. World J Mens Health 40:74-86.

Culp M. B., Soerjomataram I., Efstathiou J. A., Bray F. and Jemal A. (2020) Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates. European Urology 77:38-52.

Daniyal M., Siddiqui Z. A., Akram M., Asif H. M., Sultana S. and Khan A. (2014) Epidemiology, etiology, diagnosis and treatment of prostate cancer. Asian Pacific Journal of Cancer Prevention 15:9575-9578.

Eeles R. A., Olama A. A., Benlloch S., Saunders E. J., Leongamornlert D. A., Tymrakiewicz M.,  et al. (2013) Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nature Genetics 45:385-391, 391e381-382.

Fleming W. H., Hamel A., MacDonald R., Ramsey E., Pettigrew N. M., Johnston B.,et al. (1986) Expression of the c-myc protooncogene in human prostatic carcinoma and benign prostatic hyperplasia. Cancer Research 46:1535-1538.

Freedman M. L., Haiman C. A., Patterson N., McDonald G. J., Tandon A., Waliszewska A.,et al. (2006) Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proceedings of the National Academy of Sciences of the United States of America 103:14068-14073.

Gandaglia G., Leni R., Bray F., Fleshner N., Freedland S. J., Kibel A.,et al. (2021) Epidemiology and Prevention of Prostate Cancer. Eur Urol Oncol 4:877-892.

Gu Y., Lin X., Kapoor A., Chow M. J., Jiang Y., Zhao K.,et al. (2020) The Oncogenic Potential of the Centromeric Border Protein FAM84B of the 8q24.21 Gene Desert. Genes (Basel) 11.

Hayes R. B., Ziegler R. G., Gridley G., Swanson C., Greenberg R. S., Swanson G. M.,et al. (1999) Dietary factors and risks for prostate cancer among blacks and whites in the United States. Cancer Epidemiol Biomarkers Prev 8:25-34.

Henríquez-Hernández L. A., Valenciano A., Foro-Arnalot P., Álvarez-Cubero M. J., Cozar J. M., Suárez-Novo J. F.,et al. (2014) Single nucleotide polymorphisms in DNA repair genes as risk factors associated to prostate cancer progression. BMC Medical Genetics 15:143.

Henríquez-Hernández L. A., Valenciano A., Foro-Arnalot P., Álvarez-Cubero M. J., Cozar J. M., Suárez-Novo J. F.,et al. (2015) Genetic variations in genes involved in testosterone metabolism are associated with prostate cancer progression: A Spanish multicenter study. Urologic Oncology 33:331.e331-337.

Hubbard G. K., Mutton L. N., Khalili M., McMullin R. P., Hicks J. L., Bianchi-Frias D.,et al. (2016) Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer. Cancer Research 76:283-292.

Kiltie A. E. (2010) Common predisposition alleles for moderately common cancers: bladder cancer. Curr Opin Genet Dev 20:218-224.

Kobayashi M. (1990) [Studies on trace elements in cancerous stomach tissue of the patients with stomach cancer]. Hokkaido Igaku Zasshi. Hokkaido Journal of Medical Science 65:320-335.

Li R., Qin Z., Tang J., Han P., Xing Q., Wang F.,et al. (2017) Association between 8q24 Gene Polymorphisms and the Risk of Prostate Cancer: A Systematic Review and Meta-Analysis. Journal of Cancer 8:3198-3211.

Li X. H., Xu Y., Yang K., Shi J. J., Zhang X., Yang F.,et al. (2015) Association of THADA, FOXP4, GPRC6A/RFX6 genes and 8q24 risk alleles with prostate cancer in Northern Chinese men. Journal of B.U.ON. 20:1223-1228.

Ling H., Spizzo R., Atlasi Y., Nicoloso M., Shimizu M., Redis R. S.,et al. (2013) CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Research 23:1446-1461.

Liu M., Wang J., Xu Y., Wei D., Shi X. and Yang Z. (2012) Risk loci on chromosome 8q24 are associated with prostate cancer in northern Chinese men. Journal of Urology 187:315-321.

Liu X., Wei D., Jiang J., Liu X., Tu R., Luo Z.,et al. (2020) Associations of SRD5A1 gene variants and testosterone with dysglycemia: Henan Rural Cohort study. Nutrition, Metabolism, and Cardiovascular Diseases 30:599-607.

McConnell J. D., Barry M. J. and Bruskewitz R. C. (1994) Benign prostatic hyperplasia: diagnosis and treatment. Agency for Health Care Policy and Research. Clinical Practice Guideline: Quick Reference Guide for Clinicians:1-17.

Moradi A., Zamani M. and Moudi E. (2019) A systematic review and meta-analysis on incidence of prostate cancer in Iran. Health Promot Perspect 9:92-98.

Oskina N. A., Boyarskikh U. A., Lazarev A. F., Petrova V. D., Ganov D. I., Tonacheva O. G.,et al. (2014) A replication study examining association of rs6983267, rs10090154, and rs1447295 common single nucleotide polymorphisms in 8q24 region with prostate cancer in Siberians. Urologic Oncology 32:37.e37-12.

Platz E. A. and Ggiovancini E. (2006)1128Prostate Cancer. In Cancer Epidemiology and Prevention. D. Schottenfeld and J.F. Fraumeni, editors. Oxford University Press. 0.

Rebbeck T. R. (2017) Prostate Cancer Genetics: Variation by Race, Ethnicity, and Geography. Seminars in Radiation Oncology 27:3-10.

Roudgari H., Hemminki K., Brandt A., Sundquist J. and Fallah M. (2012) Prostate cancer risk assessment model: a scoring model based on the Swedish Family-Cancer Database. Journal of Medical Genetics 49:345-352.

Setlur S. R., Chen C. X., Hossain R. R., Ha J. S., Van Doren V. E., Stenzel B.,et al.(2010) Genetic variation of genes involved in dihydrotestosterone metabolism and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 19:229-239.

Shafiee G., Mousavian A. H., Sheidaei A., Ebrahimi M., Khatami F., Gohari K.,et al.(2023) The 15-year national trends of genital cancer incidence among Iranian men and women; 2005-2020. BMC Public Health 23:495.

Siegel R. L., Miller K. D., Fuchs H. E. and Jemal A. (2022) Cancer statistics, 2022. CA: A Cancer Journal for Clinicians 72:7-33.

Stanczyk F. Z., Azen C. G. and Pike M. C. (2013) Effect of finasteride on serum levels of androstenedione, testosterone and their 5α-reduced metabolites in men at risk for prostate cancer. J Steroid Biochem Mol Biol 138:10-16.

Wilson C. and Kanhere A. (2021) 8q24.21 Locus: A Paradigm to Link Non-Coding RNAs, Genome Polymorphisms and Cancer. International Journal of Molecular Sciences 22.

Zhang X., Chen Q., He C., Mao W., Zhang L., Xu X.,et al.(2012) Polymorphisms on 8q24 are associated with lung cancer risk and survival in Han Chinese. PloS One 7:e41930.

Zhu Y., Mo M., Wei Y., Wu J., Pan J., Freedland S. et al. (2021) Epidemiology and genomics of prostate cancer in Asian men. Nat Rev Urol 18:282-301.